$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224033091 Filed on August 19, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue		$30.91K	$13.29K
YoY Change		132.55%	112.31%
Cost Of Revenue		$21.08K	$18.53K
YoY Change		13.76%	8.1%
Gross Profit		$9.834K	-$5.236K
YoY Change		-287.82%	-51.87%
Gross Profit Margin		31.81%	-39.39%
Selling, General & Admin		$875.6K	$870.1K
YoY Change		0.64%	4.05%
% of Gross Profit		8904.1%
Research & Development		$155.7K	$139.0K
YoY Change		11.96%	-13.01%
% of Gross Profit		1583.09%
Depreciation & Amortization		$380.00	$273.00
YoY Change		39.19%	-65.83%
% of Gross Profit		3.86%
Operating Expenses		$1.031M	$1.009M
YoY Change		2.2%	1.31%
Operating Profit		-$1.021M	-$1.014M
YoY Change		0.7%	0.73%
Interest Expense		-$671.9K	$808.8K
YoY Change		-183.08%	1927.5%
% of Operating Profit
Other Income/Expense, Net		-$4.633M	-$808.8K
YoY Change		472.87%	1927.5%
Pretax Income		-$5.655M	-$1.823M
YoY Change		210.17%	74.16%
Income Tax
% Of Pretax Income
Net Earnings		-$5.655M	-$1.823M
YoY Change		210.17%	74.16%
Net Earnings / Revenue		-18292.24%	-13714.79%
Basic Earnings Per Share		-$1.44	-$1.42
Diluted Earnings Per Share		-$1.44	-$1.42
COMMON SHARES
Basic Shares Outstanding	4.444M shares	4.444M	1.285M
Diluted Shares Outstanding		4.444M shares	1.280M shares

Balance Sheet

Concept	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.03K	$86.54K
YoY Change	-65.3%	57.35%
Cash & Equivalents	$30.03K	$86.54K
Short-Term Investments
Other Short-Term Assets	$40.82K	$90.54K
YoY Change	-54.91%	8.44%
Inventory	$1.320M	$1.383M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.391M	$1.560M
YoY Change	-10.83%	-0.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.014K	$728.00
YoY Change	314.01%	-74.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.500K	$3.500K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$6.514K	$4.228K
YoY Change	54.07%	-33.34%
TOTAL ASSETS
Total Short-Term Assets	$1.391M	$1.560M
Total Long-Term Assets	$6.514K	$4.228K
Total Assets	$1.398M	$1.564M
YoY Change	-10.65%	-0.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.917M	$2.471M
YoY Change	18.03%	45.69%
Accrued Expenses	$1.653M	$1.021M
YoY Change	61.93%	357.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.388M	$5.347M
YoY Change	75.58%
Total Short-Term Liabilities	$13.96M	$9.579M
YoY Change	45.71%	399.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities		$0.00
YoY Change		-100.0%
Total Long-Term Liabilities	$0.00	$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.96M	$9.579M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$13.96M	$9.579M
YoY Change	45.71%	71.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.59M	-$59.60M
YoY Change	21.8%	12.06%
Common Stock	$60.03M	$51.58M
YoY Change	16.38%	21665.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.56M	-$8.015M
YoY Change
Total Liabilities & Shareholders Equity	$1.398M	$1.564M
YoY Change	-10.65%	-0.56%

Cashflow Statement

Concept	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$5.655M	-$1.823M
YoY Change	210.17%	74.16%
Depreciation, Depletion And Amortization	$380.00	$273.00
YoY Change	39.19%	-65.83%
Cash From Operating Activities	-$911.7K	-$897.5K
YoY Change	1.57%	56.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	915.2K	954.6K
YoY Change	-4.12%	66.02%
NET CHANGE
Cash From Operating Activities	-911.7K	-897.5K
Cash From Investing Activities
Cash From Financing Activities	915.2K	954.6K
Net Change In Cash	3.600K	57.04K
YoY Change	-93.69%	9567.8%
FREE CASH FLOW
Cash From Operating Activities	-$911.7K	-$897.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	ARTH	Financing Expense FinancingExpense		usd
	ARTH	Financing Expense FinancingExpense		usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives		usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives		usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives		usd
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2024Q1	ARTH	Stock Issued During Period Value Warrants Exchanged StockIssuedDuringPeriodValueWarrantsExchanged		usd
CY2024Q2	ARTH	Deemed Dividends For Down Round Provision In Warrants DeemedDividendsForDownRoundProvisionInWarrants		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	ARTH	Relative Fair Value Of Warrants Issued Convertible Notes Payable Unsecured RelativeFairValueOfWarrantsIssuedConvertibleNotesPayableUnsecured		usd
	ARTH	Non Cash Deemed Dividends On Warrants Upon Trigger Of Down Round Provision NonCashDeemedDividendsOnWarrantsUponTriggerOfDownRoundProvision		usd
	ARTH	Warrants Exchanged For Common Stock Noncash WarrantsExchangedForCommonStockNoncash		usd
	ARTH	Issuance Of Restricted Stock IssuanceOfRestrictedStock		usd
	ARTH	Fair Value Of Warrants Issued FairValueOfWarrantsIssued		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	ARTH	Fair Value Of Placement Agent Warrants FairValueOfPlacementAgentWarrants		usd
	ARTH	Fair Value Of Warrants Issued One FairValueOfWarrantsIssuedOne		usd
	ARTH	Stock Issued2 StockIssued2		usd
	ARTH	Conversion Of Shareholder Advance Into Unsecured Convertible Note ConversionOfShareholderAdvanceIntoUnsecuredConvertibleNote		usd
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	ARTH	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-54986
	dei	Entity Registrant Name EntityRegistrantName	ARCH THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-0524102
	dei	Entity Address Address Line1 EntityAddressAddressLine1	235 Walnut Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 6
	dei	Entity Address City Or Town EntityAddressCityOrTown	Framingham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01702
	dei	City Area Code CityAreaCode	(617)
	dei	Local Phone Number LocalPhoneNumber	431-2313
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4444364	shares
CY2024Q2	us-gaap	Cash Cash	30030	usd
CY2023Q3	us-gaap	Cash Cash	222720	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1320276	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1364504	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40824	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	362866	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	1391130	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1950090	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3014	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4599	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3500	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3500	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	6514	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	8099	usd
CY2024Q2	us-gaap	Assets Assets	1397644	usd
CY2023Q3	us-gaap	Assets Assets	1958189	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2916655	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2304207	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	407242	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	467496	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	1246092	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	823128	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13958210	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9465921	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4444364	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4444364	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4689446	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4689446	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	4444	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	4689	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	60026073	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	54543188	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72591083	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62055609	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-12560566	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7507732	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1397644	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1958189	usd
CY2024Q2	us-gaap	Revenues Revenues	30913	usd
CY2023Q2	us-gaap	Revenues Revenues	13293	usd
	us-gaap	Revenues Revenues	108646	usd
	us-gaap	Revenues Revenues	36207	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	21079	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	18529	usd
	us-gaap	Cost Of Revenue CostOfRevenue	66240	usd
	us-gaap	Cost Of Revenue CostOfRevenue	54882	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	875629	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	870053	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2870163	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3225753	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	155681	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	139048	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	565130	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	471135	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	1052389	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	1027630	usd
	us-gaap	Costs And Expenses CostsAndExpenses	3501533	usd
	us-gaap	Costs And Expenses CostsAndExpenses	3751770	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1021476	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1014337	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3392887	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3715563	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	671929	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	808770	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2451309	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1968274	usd
CY2024Q2	ARTH	Financing Expense FinancingExpense	3961276	usd
	ARTH	Financing Expense FinancingExpense	3961276	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	1158197	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4633205	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-808770	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6412585	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-810077	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5654681	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1823107	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9805472	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4525640	usd
CY2024Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730002	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730002	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6384683	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1823107	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10535474	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4525640	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.44
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.44
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.42
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.42
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.58
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4444364	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4444364	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1279967	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1279967	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4550264	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4550264	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1265340	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1265340	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-7507732	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-2681652	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	587959	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25909	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9575516	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1469139	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	18280	usd
CY2024Q1	ARTH	Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts	148891	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10877484	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5654681	usd
CY2024Q2	ARTH	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	3961276	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10323	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-12560566	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4192803	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1800056	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	104026	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5888833	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-902477	usd
CY2023Q1	ARTH	Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts	287420	usd
CY2023Q1	ARTH	Stock Issued During Period Value Warrants Exchanged StockIssuedDuringPeriodValueWarrantsExchanged	49278	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	68524	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-6386088	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-6386088	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1823107	usd
CY2023Q2	ARTH	Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts	152908	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	41259	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-8015028	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-8015028	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9805472	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4525640	usd
	us-gaap	Depreciation Depreciation	1585	usd
	us-gaap	Depreciation Depreciation	1316	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	36232	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	213809	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3961276	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	1158197	usd
	us-gaap	Accretion Expense AccretionExpense	1852588	usd
	us-gaap	Accretion Expense AccretionExpense	1480121	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-44228	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-31910	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-322041	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-345869	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	612449	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1143162	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	560922	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	488153	usd
	ARTH	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-60254	usd
	ARTH	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-167983	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2474405	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2147480	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	243285	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	247933	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1228015	usd
	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	450000	usd
	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	507000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2075000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2281715	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1487082	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-192690	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-660398	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	222720	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	746940	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30030	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86542	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	606239	usd
	ARTH	Relative Fair Value Of Warrants Issued Convertible Notes Payable Unsecured RelativeFairValueOfWarrantsIssuedConvertibleNotesPayableUnsecured	148891	usd
	ARTH	Non Cash Deemed Dividends On Warrants Upon Trigger Of Down Round Provision NonCashDeemedDividendsOnWarrantsUponTriggerOfDownRoundProvision	730002	usd
	ARTH	Warrants Exchanged For Common Stock Noncash WarrantsExchangedForCommonStockNoncash	49278	usd
	ARTH	Issuance Of Restricted Stock IssuanceOfRestrictedStock	3019	usd
	ARTH	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	256439	usd
	us-gaap	Stock Issued1 StockIssued1	25840	usd
	ARTH	Fair Value Of Placement Agent Warrants FairValueOfPlacementAgentWarrants	28093	usd
	ARTH	Fair Value Of Warrants Issued One FairValueOfWarrantsIssuedOne	137252	usd
	ARTH	Stock Issued2 StockIssued2	15656	usd
	ARTH	Conversion Of Shareholder Advance Into Unsecured Convertible Note ConversionOfShareholderAdvanceIntoUnsecuredConvertibleNote	488000	usd
CY2024Q2	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
	us-gaap	Net Income Loss NetIncomeLoss	-9805472	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2474405	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 1:200, effective January 17, 2023
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zTyXytlKJtId" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zJ4ZtyDHlveg">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of equity instruments issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730002	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730002	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5654681	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1823107	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9805472	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4525640	usd
CY2024Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730002	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730002	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6384683	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1823107	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10535474	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4525640	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	48601375	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1891417	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z1ZWpewgE7Yc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zuYNLPHIekJk">Concentration of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	56663	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	40969	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1263613	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1323535	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1320276	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1364504	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2024Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	300000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	102125	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.00
CY2023	ARTH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P5Y6M29D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1825	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	67.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	100300	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.00
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12025	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	58.00
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	88275	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.00
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	250	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	58.00
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	88025	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.00
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	77812	shares
CY2024Q2	ARTH	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	40.00
CY2024Q2	ARTH	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P3Y3M
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	36232	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	210789	usd
CY2024Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730002	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730002	usd
CY2024Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	usd
CY2023Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	3000	usd

Files In Submission

Name	View Source	Status
0001493152-24-033091-index-headers.html	Edgar Link	pending
0001493152-24-033091-index.html	Edgar Link	pending
0001493152-24-033091.txt	Edgar Link	pending
0001493152-24-033091-xbrl.zip	Edgar Link	pending
arth-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
arth-20240630_def.xml	Edgar Link	unprocessable
arth-20240630_lab.xml	Edgar Link	unprocessable
arth-20240630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
arth-20240630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2024 Q3 Form 10-Q Financial Statement

#000149315224033091 Filed on August 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2024 Q3 Form 10-Q Financial Statement

#000149315224033091 Filed on August 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth